Inicio・Lista de Acciones・UCB SA

UCB SA

Abierto

166.4 2.53

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

162.25

Máximo

167.1

Métricas clave
By Trading Economics
Ingresos	104M
Ventas	127M 2.8B
P/B Media del Sector	26.67
BPA	2.09
Margen de beneficio	3.728

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+19.23 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-180M 31B
Apertura anterior	163.87
Cierre anterior	166.4

Noticias sobre sentimiento de mercado

By Acuity

100%

UCB SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 dic 2023, 16:47 UTC

Charlas de Mercado

European Pharmas With New Drugs Hold Most Promise in 2024 -- Market Talk

UCB SA Esperado

Precio Objetivo

By TipRanks

19.23% repunte

Estimación a 12 meses

Media 94.86 EUR 19.23%

Máximo 125 EUR

Mínimo 74 EUR

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para UCB SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para UCB SA Dist en los últimos 3 meses.

Sentimiento

By Acuity

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de UCB SA

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.